Cobimetinib
| CAS No. | 934660-93-2 |
|---|---|
| MDL No. | MFCD22124461 |
| MF | C21H21F3IN3O2 |
| MW | 531.30 |
| InChI Key | BSMCAPRUBJMWDF-KRWDZBQOSA-N |
Pricing & Availability
| Pack Size | Purity | Price | Availability | Action |
|---|---|---|---|---|
| - | - | On Request | On Request | |
| Custom synthesis and bulk supply options are available upon request. | ||||
Product Information
Cobimetinib is an N-acylazetidine derived from the selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. It is a mitogen-activated protein kinase inhibitor used in combination with vemurafenib to treat unresectable or metastatic melanoma, administered as its fumarate salt. Cobimetinib functions as an EC 2.7.11.24 inhibitor and antineoplastic agent. It belongs to piperidines, N-acylazetidines, tertiary alcohols, aromatic amines, secondary amino compounds, difluorobenzenes, and organoiodine compounds. It is the conjugate base of cobimetinib(1+).
| CAS No. | 934660-93-2 |
|---|---|
| Product Name | Cobimetinib |
Biological Targets
MAP2K1·MAP2K2
Associated Conditions
chronic myelomonocytic leukemia·pancreatic carcinoma·cutaneous melanoma·Cerebral arteriovenous malformation·thyroid carcinoma·
* The information provided here is compiled from public sources and is for reference only.